Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks

  • Ascendis Pharma A/S ASND announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP). 
  • Hypoparathyroidism is a condition in which the body produces abnormally low levels of PTH, the key to regulating and maintaining a balance of two calcium and phosphorus.
  • TransCon PTH is an investigational once-daily prodrug of parathyroid hormone (PTH) designed to restore physiologic levels of PTH 24 hours a day. 
  • The week 84 data showed that subjects treated with TransCon PTH had mean serum calcium levels and urinary calcium excretion that remained stable and normal.
  • Most subjects (93%) continued to be free from taking active vitamin D and were taking less than 600 mg/day of calcium supplements.
  • TransCon PTH was well-tolerated at all doses administered. 
  • No treatment-related severe adverse events occurred, and no treatment-emergent adverse events led to the discontinuation of the study drug.
  • The Company will share topline Phase 3 data in Q1 of 2022 and, if positive, plan to complete a marketing application submission to the FDA in mid-2022.
  • Related: See Why Ascendis Pharma Stock Is Shining On Thursday.
  • Price Action: ASND shares closed at $148.64 on Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!